Crossmark

Treatment of Shengqingtongqiao Decoction for mild cognitive impairment of white matter lesions study protocol for a randomized, double-blind, double-dummy, parallel controlled trial

Crossref DOI link: https://doi.org/10.1186/s12906-024-04654-4

Published Online: 2024-10-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Han, XueYi

Zhang, JieQing

Wei, ZiJun

Mei, JiaNing

Long, Xie

Zhen, XiaoMin

Zhang, YueChan

Zhang, YunYun
License Information

Text and Data Mining valid from 2024-10-11

Version of Record valid from 2024-10-11
More Information

Article History

Received: 11 April 2024

Accepted: 20 September 2024

First Online: 11 October 2024

Declarations

:

: This study protocol was reviewed and approved by the Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, approval number [2021-138].

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below